Endometrial cancer research hub

A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Fadraciclib (CYC065), an Oral CDK2/9 Inhibitor, in Subjects with Advanced Solid Tumors and Lymphoma.

This study is testing a new medicine called Fadraciclib for advanced cancers like endometrial, ovarian, and some lymphomas. It aims to see if it's safe, how it works in the body, and if it can shrink tumors or stop cancer growth. It's for adults aged 18 and over.